More importantly, it blocks the EGFR pathway with its antagonist erlotinib abrogated LRIG1 suppression-induced EMT and, subsequently, cell invasion, migration, and vasculogenic mimicry of melanoma cells under hypoxia [41]. The gene discussed is EGFR; the disease is melanoma.